Abstracts Archive - Page 1788 of 2607 - ACR Meeting Abstracts

Abstract Number: 2839 • 2016 ACR/ARHP Annual Meeting
Circulating CD4+CD28null T-Cells Predict the Occurrence of New Lung Damage in Systemic Lupus Erythematosus (SLE) Patients
Manuel Ugarte-Gil^1,2, César Sánchez-Zúñiga³, Rocio V. Gamboa-Cardenas¹, Madeley Aliaga-Zamudio⁴, Francisco Zevallos¹, Ana Mosqueira-Riveros⁴, Mariela Medina¹, Giannina Tineo-Pozo⁴, Claudia Elera-Fitzcarrald¹, Victor Pimentel-Quiroz¹, Omar Sarmiento-Velasquez¹, Jorge M. Cucho-Venegas¹, Jose Alfaro-Lozano¹, Zoila Rodriguez-Bellido^1,5, Cesar A. Pastor-Asurza^1,5, Graciela S. Alarcón⁶ and Risto Perich-Campos^1,5, ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Universidad Cientifica del Sur, Lima, Peru, ³Diagnostic Support, Hospital Grau. EsSalud, Lima, Peru, ⁴Molecular Biology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁵Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Peripheral CD4+CD28null T-cells constitute a subset of long-lived cytotoxic CD4+ T-cell with pro-inflammatory functions. This T-cell subpopulation has been reported to be associated with…
Abstract Number: 2840 • 2016 ACR/ARHP Annual Meeting
Are There Genetic Predispositions to Diffuse Large B-Cell Lymphoma (DLBCL) in Systemic Lupus (SLE)?
Sasha Bernatsky¹, Ann E. Clarke², Rosalind Ramsey-Goldman³, Patrick Gaffney⁴, John Spinelli⁵, Sophia Wang⁶ and Timothy J. Vyse⁷, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³FSM, Northwestern University, Chicago, IL, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵School of Population and Public Health, University of British Columbia, Vancouver, QC, Canada, ⁶Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, Duarte, CA, ⁷Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
Are there genetic predispositions to diffuse large B-cell lymphoma (DLBCL) in systemic lupus (SLE)? Sasha Bernatsky1, Ann E. Clarke2, Rosalind Ramsey-Goldman3, Patrick M. Gaffney4,…
Abstract Number: 2841 • 2016 ACR/ARHP Annual Meeting
Anti-Ro52/TRIM21 Antibodies Are Associated with QT Interval Prolongation in Patients with Systemic Lupus Erythematosus
Luis F. Perez-Garcia¹, Irving Omar Estevez-Garcia¹, Mariana Moreno Ramirez¹, Javier Loaiza Felix¹, Ricardo Marquez-Velasco², Pedro Iturralde³, Luis H. Silveira^4,5 and Luis M. Amezcua-Guerra¹, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ²Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ³Cardiology - Electrophysiology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁴Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ⁵Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico
Background/Purpose: Long QT syndrome (LQTS) is characterized by an abnormal QT corrected (QTc) interval prolongation that is associated with increased risk of sudden death. Studies…
Abstract Number: 2842 • 2016 ACR/ARHP Annual Meeting
Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis
William Fung¹, Jiandong Su² and Zahi Touma³, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) manifests with proteinuria and/or active urine sediment. Renal composite indices include proteinuria, urinary active sediment (RBCs, casts) and serum creatinine.…
Abstract Number: 2843 • 2016 ACR/ARHP Annual Meeting
Prevalence of Anti-DFS70 Antibodies in Patients with and without Systemic Autoimmune Rheumatic Diseases
Ora Shovman¹, Boris Gilburd², Chen Chayat³, Howard Amital^1,4, Abdulla Watad⁵, Adi Guy⁵, Chelsea Bentow⁶, Michael Mahler⁶ and Yehuda Shoenfeld^1,4, ¹Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat Gan, Israel, ²Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat-Gan, Israel, ³Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat Gan, Israel, ⁴Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, Tel-Aviv, Israel, ⁵Internal Medicine B, Internal Medicine B, Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat Gan, Israel, ⁶Research and Development, Inova Diagnostics, San Diego, CA
Background/Purpose: Autoantibodies to the dense fine speckled 70 (DFS70) antigen are common among ANA (dense fine speckled pattern) positive healthy individuals and consequently reduce the…
Abstract Number: 2844 • 2016 ACR/ARHP Annual Meeting
Immunoglobulins Level and Risk of Infection in Systemic Lupus Erythematosus
Ibrahim Almaghlouth¹, Jiandong Su², Dafna D Gladman³ and Murray Urowitz⁴, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patients with SLE have been followed prospectively at 2-6 month intervals according to a standard protocol, which includes detailed clinical and laboratory assessments including…
Abstract Number: 2845 • 2016 ACR/ARHP Annual Meeting
Antineutrophil Cytoplasmic Antibodies in Systemic Lupus Erythematosus: Incidence, Outcome and Prognosis
Abdullah Almutlaq¹, Murray Urowitz¹, Jiandong Su² and Dafna D Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: The presence of ANCA in SLE had been known for over 25 years with a reported prevalence as high as 31%. However, the relationship…
Abstract Number: 2846 • 2016 ACR/ARHP Annual Meeting
Application of a Novel Anti-Nuclear Antibody Multiplex Test Using Finger Stick and Venous Whole Blood in a Rheumatology Clinic – Demonstration of Feasibility
Smitha Reddy¹, Dana Copland Reddy², Rufus Burlingame³, Vicki Nelson⁴, Carol Buchner⁴, John Stewart⁵, Sasi Mudumba⁵, John Custodio⁵, Jue Wang⁵, Randy Romero⁵, Alice Wu⁶, Carli Cherwein⁵, Simon Smith⁵ and Martin A. Gleeson⁴, ¹Arthritis Care and Research Center, San Diego, CA, ²SD Rheumatology, Chula Vista, CA, ³Genaltye, San Diego, CA, ⁴Genalyte, Wateridge circle, CA, ⁵Genalyte, San Diego, CA, ⁶Genalyte, Inc., San Diego, CA
Background/Purpose: Multiplex assays that measure anti-nuclear autoantibodies (ANA) in real time using whole blood were developed on the Maverick(TM) instrument (Genalyte, Inc., USA). Because the…
Abstract Number: 2847 • 2016 ACR/ARHP Annual Meeting
Antibodies to Double Stranded DNA: Combined Standard ELISA and High-Salt ELISA Assays for the Detection of SLE Disease Activity
Laura Durcan, Jenna Thomason, Daniel Kuo and Mark H. Wener, University of Washington, Seattle, WA
Background/Purpose: Serological markers in systemic lupus erythematosus (SLE) are crucial objective measures included in disease activity indices. Antibodies to double stranded DNA (anti-dsDNA) are included…
Abstract Number: 2848 • 2016 ACR/ARHP Annual Meeting
Near Patient Anti-Nuclear Antibody Multiplex Testing Using Whole Blood for the Diagnosis of Connective Tissue Diseases in a Tertiary Care Center
Makoto Miyara¹, Jean- Luc Charuel², Sasi Mudumba³, Alice Wu³, Pascale Ghillani-Dalbin², Zahir Amoura^4,5,6, Rufus Burlingame⁷ and Lucile Musset¹, ¹Department of immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Genalyte, Inc., San Diego, CA, ⁴Internal Medecine - Centre de Référence National pour les Lupus et et le Syndrome des Antiphospholipides, Internal Medecine - Centre de Référence National pour les Lupus et et le Syndrome des Antiphospholipides, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁵Department of Internal Medicine 2. Referal center for SLE/APS, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁶Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁷Genaltye, San Diego, CA
Background/Purpose: Detection of anti-nuclear antibodies for the diagnosis of connective tissue diseases (CTD) often requires complex algorithms to obtain conclusive results , including immunofluorescence on…
Abstract Number: 2849 • 2016 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Patients with Antibodies Against U1-Ribonucleoprotein Exhibit a Specific Pattern of Disease Manifestations
David Fernandez¹, Mikhail Olferiev¹, Leila Khalili¹, Kyriakos A. Kirou² and Mary K. Crow¹, ¹Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies against nucleic acids and a variety of self-antigens. Recent work…
Abstract Number: 2850 • 2016 ACR/ARHP Annual Meeting
Changes in Urinary Biomarker Levels Can Predict Treatment Responses in Lupus Nephritis
Joan Wither¹, Stephenie Prokopec², Babak Noamani¹, Dennisse Bonilla¹, Zahi Touma³, Carmen Avila-Casado⁴, Heather Reich⁵, James Scholey⁵, Paul R. Fortin⁶, Paul Boutros² and Carolina Landolt-Marticorena¹, ¹Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Ontario Institute for Cancer Research, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Pathology, University Health Network, Toronto, ON, Canada, ⁵Nephrology, University Health Network, Toronto, ON, Canada, ⁶Université Laval, CHU de Québec, Québec, QC, Canada
Background/Purpose: The relapsing and remitting nature of lupus nephritis (LN) poses a challenge to clinicians who must balance the risk of long term kidney damage…
Abstract Number: 2851 • 2016 ACR/ARHP Annual Meeting
An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice
Donald Massenburg, Justine Oldenberg, Amanda Sell, Tristan Krause and Alvin F. Wells, Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: The SLE-key® test to Rule Out lupus was developed by ImmunArray Ltd using serum samples of 246 SLE patients and 252 self-declared healthy controls.…
Abstract Number: 2852 • 2016 ACR/ARHP Annual Meeting
Long Term Prognosis of Lupus Nephritis in the Afro-Caribbean Population of Martinique with Free Access to Healthcare
Aymeric Couturier¹, Vincent Molinie², Charles Cartou³, Serge ARFI⁴, Violaine Emal-Aglae⁵, Katlyne Polomat⁶, Florence MOINET⁶, Georges JEAN BAPTISTE⁷ and Christophe Deligny⁸, ¹nephrology, Pierre Zobda Quitman hospital, Fort de France, Martinique, ²Pathology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, ³nephrology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, ⁴University Hospital, CHU Fort de France, Fort de France, Martinique, ⁵Nephrology, Centre Hospitalier de Mangot-Vulcin, Le Lamentin, Martinique, ⁶Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort de France, Martinique, ⁷RHEUMATOLOGY, CHU MARTINIQUE, FWI, Fort-de-France, Martinique, ⁸Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique
Background/Purpose: In African-descent patients, lupus nephritis (LN) lead to a worse outcome than in Caucasians. Long term data are rare in countries where black populations…
Abstract Number: 2853 • 2016 ACR/ARHP Annual Meeting
Neutrophilia in Systemic Lupus Erythematosus As a Potential Indicator of Disease Activity
Emily E. Lewis¹, W Joseph McCune² and Jason S Knight³, ¹University of Michigan, Ann Arbor, MI, ²Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Neutrophilia and elevated neutrophil-to-lymphocyte ratio are being increasingly recognized as reliable markers of inflammation (and usually negative prognostic outcome) in scenarios as diverse as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].